{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Zhang J"],"pubmed_abstract":["<h4>Introduction</h4>Epidemiological studies investigating the association between carnitine and breast cancer are scarce.<h4>Materials and methods</h4>This 1:1 age-matched retrospective case-control study identified 991 female breast cancer cases and 991 female controls without breast cancer using pathological testing. We used targeted metabolomics technology to measure 16 types of whole blood carnitine compounds, such as free carnitine (C0) and octadecanoylcarnitine (C18).<h4>Results</h4>The average age for cases and controls was approximately 50 ± 8.7 years. After adjusting for covariates, each standard deviation (SD) increase in malonylcarnitine (C3DC; OR 0.91; 95% CI 0.83-1.00), decenoylcarnitine (C10:1; OR 0.87; 95% CI 0.79-0.96), and decadienoylcarnitine (C10:2; OR 0.90; 95% CI 0.82"],"journal":["Frontiers in oncology"],"pagination":["891619"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9300951"],"repository":["biostudies-literature"],"pubmed_title":["Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study."],"pmcid":["PMC9300951"],"pubmed_authors":["Li J","Tao W","Zhang J","Vuong AM","Zhu H","Wu G","Yang S","Sun Y","Yang F","Zhu D"],"additional_accession":[]},"is_claimable":false,"name":"Circulating Carnitine Levels and Breast Cancer: A Matched Retrospective Case-Control Study.","description":"<h4>Introduction</h4>Epidemiological studies investigating the association between carnitine and breast cancer are scarce.<h4>Materials and methods</h4>This 1:1 age-matched retrospective case-control study identified 991 female breast cancer cases and 991 female controls without breast cancer using pathological testing. We used targeted metabolomics technology to measure 16 types of whole blood carnitine compounds, such as free carnitine (C0) and octadecanoylcarnitine (C18).<h4>Results</h4>The average age for cases and controls was approximately 50 ± 8.7 years. After adjusting for covariates, each standard deviation (SD) increase in malonylcarnitine (C3DC; OR 0.91; 95% CI 0.83-1.00), decenoylcarnitine (C10:1; OR 0.87; 95% CI 0.79-0.96), and decadienoylcarnitine (C10:2; OR 0.90; 95% CI 0.82","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T23:23:59.212Z","creation":"2025-04-06T17:34:55.172Z"},"accession":"S-EPMC9300951","cross_references":{"pubmed":["35875107"],"doi":["10.3389/fonc.2022.891619"]}}